Stockscreener 앱 받기
38.43
6.54%
-2.69
전일 마감가:
$41.12
열려 있는:
$41.11
하루 거래량:
1.15M
Relative Volume:
0.81
시가총액:
$4.13B
수익:
-
순이익/손실:
$-176.01M
주가수익비율:
-23.14
EPS:
-1.661
순현금흐름:
$-148.97M
1주 성능:
-5.90%
1개월 성능:
-5.41%
6개월 성능:
+36.52%
1년 성능:
+169.50%
1일 변동 폭
$38.21
$41.11
1주일 범위
$38.21
$42.38
52주 변동 폭
$12.30
$48.40
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
38.43 | 4.48B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Goldman | Neutral |
| 2025-07-30 | 개시 | Raymond James | Strong Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
EWTX|Edgewise Therapeutics Inc|Price:41.590|Chg%:+0.750 - TradingKey
Edgewise Therapeutics Inc (EWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edgewise Therapeutics Inc (EWTX) Balance Sheet - TradingKey
Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edgewise Therapeutics, Inc. Revenue Breakdown – NASDAQ:EWTX - TradingView
Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edgewise Therapeutics Inc (EWTX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Is Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Year - Kavout | AI
EWTX|Edgewise Therapeutics Inc|Price:40.840|Chg%:+1.550 - TradingKey
Edgewise Therapeutics, Inc. (EWTX) options chain - Yahoo Finance Singapore
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history - Yahoo Finance UK
Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified? - Yahoo Finance
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Biotechnology Innovator with a Promising 28.63% Upside - DirectorsTalk Interviews
EWTX Maintained by Evercore ISI Group -- Price Target Raised to $55 - GuruFocus
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $55 - Moomoo
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
(EWTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Form 4 Edgewise Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Edgewise Therapeutics director gets 16,377 options | EWTX Insider Trading - Stock Titan
Edgewise Therapeutics (NASDAQ: EWTX) books big gain on $1.55B sevasemten sale - Stock Titan
Frontier tech research, news & data - MLQ.ai
Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business - Macau Business
Boulder biotech unloads muscular dystrophy drug for up to $2.65 billion - The Business Journals
Edgewise closes muscular-dystrophy biz sale in deal that could top $2.6M - BizWest
Edgewise sells sevasemten business for $1.55 billion - grafa.com
Edgewise Therapeutics Sells Sevasemten for Up to $2.65 Billion to Focus on Cardiovascular Drug Pipeline - Minichart
Positive Trial Results Propel Edgewise's (EWTX) Plans for Phase 3 Development - GuruFocus
Servier completes $2.65 billion Edgewise muscular dystrophy buy By Investing.com - Investing.com Nigeria
Edgewise Therapeutics Completes Up to $2.65 Billion Sevasemten Sale to Focus on Cardiovascular Pipeline - citybiz
Edgewise completes sale of sevasemten to Servier for $2.65B By Investing.com - Investing.com Nigeria
Servier completes $2.65 billion Edgewise muscular dystrophy buy - Investing.com
Servier Acquires Muscular Dystrophy Business from Edgewise Therapeutics - Contract Pharma
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Edgewise (Nasdaq: EWTX) receives $1.55B upfront, pivots to heart drugs - Stock Titan
Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain - Trefis
Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51 - Moomoo
Servier Pharmaceuticals LLC completed the acquisition of Sevasemten and Muscular Dystrophy Business of Edgewise Therapeutics, Inc.. - marketscreener.com
Oppenheimer Initiates Edgewise Therapeutics at Outperform - Moomoo
EWTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says - Moomoo
Oppenheimer initiates Edgewise Therapeutics stock with outperform rating By Investing.com - Investing.com India
Oppenheimer initiates Edgewise Therapeutics stock with outperform rating - Investing.com
Price to book forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics stock hits all-time high at 43.96 USD - Investing.com UK
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엣지와이즈 주식 (EWTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Jul 01 '26 |
Sale |
39.41 |
200,000 |
7,881,402 |
24,555 |
2.44%
0.02%
자본화:
|
볼륨(24시간):